Biotechnology News and Research

RSS

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Report: California biomedical industry faces unprecedented challenges

The biomedical industry is one of the most recession-resilient sectors in California's hard-hit economy and a critical driver of innovation, job growth and revenue that will help lead the state to economic recovery, according to a report released today by the California Healthcare Institute (CHI) and PricewaterhouseCoopers LLP (PwC).

3 Feb 2010

Pall launches PallSep Biotech filtration system

Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.

From Pall Corporation 3 Feb 2010

New resources to support Teva Pharmaceutical Industries' Tjet injector system now available

Teva Pharmaceutical Industries Ltd. announced today the availability of new resources to support the recently introduced Tjet® injector system, a needle-free device designed to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.

3 Feb 2010

Hundred millions for biotech-licence

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).

3 Feb 2010

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

3 Feb 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

HST Global plans to develop new Clinical Treatment Facility in Ecuador

HST Global, Inc. today announced that it has targeted Ecuador for development of a Clinical Treatment Facility.

3 Feb 2010

10 new kits available for fast and simple isolation of nucleic acids from blood, plasma and serum

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 10 new kits for the fast and simple isolation of nucleic acids from blood, plasma and serum, including circulating nucleic acids.

3 Feb 2010

Pall launches Leukotrap Affinity Plus Prion and Leukocyte Reduction Filter System

Pall Corporation, a global leader in filtration, separation and purification, today announced the launch of the Leukotrap® Affinity Plus Prion and Leukocyte Reduction Filter System. The new blood filter reduces prions and leukocytes in a single step.

From Pall Corporation 3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.

3 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

Mary Ann Liebert launches Videourology journal for urologists

Videourology- is the first and only videojournal for urologists, publishing fully peer-reviewed surgical and micro-invasive video demonstrations of the latest techniques and technologies used to optimize surgical patient care.

2 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

AHM completes acquisition of Advogent Group

Advanced Health Media, LLC (AHM), the leading U.S. provider of pharmaceutical sales, marketing and compliance technology and services, announced it has acquired substantially all of the assets of Advogent Group, Inc. (Advogent), a Piscataway, NJ-based provider of marketing services for the pharmaceutical industry.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Researchers identify 1.1M base pairs of DNA in soybean genome

In 2009, soybeans represented an almost $30 billion industry in the U.S. alone, making soybeans the second-most profitable crop next to corn. Worldwide, soybeans have been used in human foods and livestock feed for centuries and have been a key component in industrial products, such as plastics and soy biodiesel, an environmentally friendly fuel.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

Biotechnology News and Research

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Report: California biomedical industry faces unprecedented challenges

Pall launches PallSep Biotech filtration system

New resources to support Teva Pharmaceutical Industries' Tjet injector system now available

Hundred millions for biotech-licence

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

HST Global plans to develop new Clinical Treatment Facility in Ecuador

10 new kits available for fast and simple isolation of nucleic acids from blood, plasma and serum

Pall launches Leukotrap Affinity Plus Prion and Leukocyte Reduction Filter System

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Mary Ann Liebert launches Videourology journal for urologists

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

AHM completes acquisition of Advogent Group

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Researchers identify 1.1M base pairs of DNA in soybean genome

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News